Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop

Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):539-545. doi: 10.1016/j.ijrobp.2020.05.018. Epub 2020 May 17.

Abstract

Purpose: On June 13 to 14, 2019, the American Society for Radiation Oncology and the Radiological Society of North America convened a workshop on the treatment of oligometastatic disease in Washington, DC. The workshop was initiated for several reasons. First, oligometastatic disease is of increasing academic and community interest and has been identified by the American Society for Radiation Oncology membership as a top research priority. Second, emerging imaging and diagnostic technologies are more readily defining and detecting oligometastatic disease, making contemporary discussion of oligometastatic disease especially relevant. Third, radiosurgery and radiation in general are theorized to be ideal noninvasive therapy for the treatment of oligometastatic disease. Finally, innovations in targeted therapy and immune therapy have the potential to reverse widely disseminating disease into an oligometastatic state.

Methods and materials: The workshop was organized into 2 keynote addresses, 6 scientific sessions, and 3 group discussions during an end-of-workshop breakout session. New scientific work was presented in the form of 4 oral presentations and a poster session. Workshop participants were charged with attempting to answer 3 critical questions: (1) Can we refine the clinical and biological definitions of oligometastatic disease; (2) how can we better treat oligometastatic disease; and (3) what clinical trials are needed?

Results: Here, we present the proceedings of the workshop.

Conclusions: The clinical implications of improved treatment of oligometastatic disease are enormous and immediate. Radiation oncology and diagnostic radiology should rightly be at the forefront of the characterization and treatment of oligometastatic disease. Focused effort is required so that we can translate current efforts of large numbers of studies with few patients to larger studies of larger impact.

Publication types

  • Congress

MeSH terms

  • Biomarkers, Tumor / analysis
  • Combined Modality Therapy / methods
  • Humans
  • Immunotherapy
  • Molecular Targeted Therapy
  • Neoplasm Metastasis* / diagnostic imaging
  • Neoplasm Metastasis* / immunology
  • Neoplasm Metastasis* / therapy
  • Physics
  • Practice Guidelines as Topic
  • Radiation Oncology / education*
  • Radiopharmaceuticals
  • Radiosurgery
  • Radiotherapy
  • Randomized Controlled Trials as Topic
  • Research
  • Societies, Medical*
  • United States

Substances

  • Biomarkers, Tumor
  • Radiopharmaceuticals